Targets › BIRC2
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jul 2027.
Multi-functional protein which regulates not only caspases and apoptosis, but also modulates inflammatory signaling and immunity, mitogenic kinase signaling, and cell proliferation, as well as cell invasion and metastasis. Acts as an E3 ubiquitin-protein ligase regulating NF-kappa-B signaling. (UniProt, Q13490)
Open in Phaseline: the race on BIRC2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Birinapant cIAP1/cIAP2 inhibitor | BIRC3, BIRC2 | Phase 1 | Locally Recurrent Head and Neck Squamous Cell Carcinoma | Jul 2027 |
Locally Recurrent Head and Neck Squamous Cell Carcinoma (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.